Strut Health vs Synergy Rx
The same $299 oral semaglutide, reached from opposite directions.
Disclosure: Buy This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
Strut Health
Partner
$99/mo
Injectable semaglutide is $149 a month, the oral $99, and tirzepatide $199 in either form. Those are auto-refill rates. Buy the oral tirzepatide once rather than on refill and it is $239, and the injection carries a $325 compare-at figure. Not sold in Alaska.
Pick it for: Buyers who want the tablet at the lower figure and will hold a refill
Synergy Rx
Partner
$299/mo
Four rates published, not two: semaglutide $199 injectable and $299 oral, tirzepatide $349 injectable and $399 oral. Most sellers quote the injection and make you fill in a form to learn the oral. Fifty states.
Pick it for: Buyers who want no standing order and all four rates visible
Our verdict
Synergy Rx charges $299 for the oral against $199 injected. Strut Health charges $99 for its oral on a standing order. The tablet is the cheap option at one and the expensive one at the other.
What actually separates them
Strut Health and Synergy Rx state different things about published price and where you can use it. Everything else they publish, they publish the same way.
Synergy Rx costs $200 more than Strut Health — 202% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $1,188 at Strut Health against $3,588 at Synergy Rx — a difference of $2,400.
| Strut Health | Synergy Rx | |
|---|---|---|
| Published price | $99/mo | $299/mo |
| Where you can use it | 49 states | 50 states |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.